
Eli Lilly leads obesity drug market with strong sales and promising pipeline, securing its top position.
Eli Lilly dominates the obesity drug market with its approved treatments Zepbound and Foundayo, showing strong sales growth—Zepbound's revenue rose 49% to $5.4 billion in Q3 2026. The company’s pipeline includes promising candidates like retatrutide ...





